Harmony Biosciences price target raised to $70 from $62 at Piper Sandler

Piper Sandler analyst David Amsellem raised the firm’s price target on Harmony Biosciences to $70 from $62 and keeps an Overweight rating on the shares. As the footprint of Harmony’s Wakix in narcolepsy continues to grow, and as expansion opportunities for the product come into focus, "there is continued room for meaningful further value creation for the shares," Amsellem tells investors in a research note. He says expansion opportunities for Wakix are now coming into focus.